The expression of BDNF mRNA has been shown to correlate with increased nodal positivity and the local recurrence rate; furthermore, treatments with anti-BDNF and anti-TrkB-T1 antibodies result in tumor growth inhibition in tumor-bearing mice, which suggests that that this protein can be used as a marker to predict adverse pathological and clinical outcomes related to breast cancers [13]. The gene discussed is NTRK2; the disease is neoplasm.